• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS 2024: Nordic Pharma to present data on canalicular gel for treatment of dry eye

News
Article

The company’s Lacrifill canalicular gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

(Image Credit: AdobeStock/Kryuchka Yaroslav)

(Image Credit: AdobeStock/Kryuchka Yaroslav)

Nordic Pharma Inc, a subsidiary of Nordic Group BV, is presenting data on Lacrifill canalicular gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in April 5 to 8 in Boston, Massachusetts.

According to the company, the canalicular gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Charlotte Phelps, CEOof Nordic Pharma, said in the news release the company is nearing the US launch of Lacrifill Canalicular Gel, “a key milestone in our global expansion strategy.”

“The recent acquisition of Visant Medical along with AmringPharmaceuticals becoming Nordic Pharma Inc, has increased our internal know-how andassets,” she added. “And with our strong US leadership team and the invaluable support of our medical advisory board, I firmly believe that Nordic Pharma is well-positioned to thrive as a new specialty ophthalmic player and enhance patient care by introducing this novel therapy for dry eye."

Eric D. Donnenfeld, MD, serves on the Lacrifill US Medical Advisory Board.

"As chairperson of the Lacrifill US Medical Advisory Board, I am excited about the potential of employing a cross-linked hyaluronic lacrimal filler to optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms” he said in the news release.

During ASCRS, the company will highlight the canalicular gel and attendees will be able to place orders for the product. The gel also will be featured during sessions during Refractive and Cornea Subspeciality Day.

A panel, titled “Lacrifill: A Paradigm Shift in Dry Eye Intervention” will be held on Saturday, April 6, and will include Donnenfeld; PreeyaGupta, MD; Darrell White, MD; and Kevin J. Corcoran, COE, CPC, CPMA, FNAO and the principal of Corcoran & Corcoran.

Mark Packer, MD, FACS, CPI, will be moderating the panel.

“As a lacrimal filler, cross-linked hyaluronic acid provides a new approach to preservation of the tear film, protecting and conforming to delicate tissues while blocking outflow,” he said in the news release. “Lacrifill canalicular gel transforms treatment of the ocular surface, with demonstrated safety and effectiveness for both signs and symptoms of dry eye.”

Jai Parekh, MD, MBA, chief commercial officer of Eye Care US, also will present data on the gel.

“I am thrilled for Nordic Pharma to be presenting data on Lacrifill canalicular gel at a meeting as important as ASCRS,” he said in the news release. “This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.